People living with HIV face unique oral health challenges that require special attention and care. The virus’s impact on the immune system creates conditions that make the mouth more vulnerable to ...

Recent medical research reveals that early HIV symptoms often masquerade as common illnesses, leading many to delay seeking medical attention. Dr. Sarah Chen, infectious disease specialist at Johns ...

Oral HPV prevalence is higher in HIV-positive mother-child pairs, with diverse high- and low-risk subtypes identified. HPV-related cancers are more prevalent in HIV-positive individuals, especially in ...

A once-daily oral combination therapy for HIV — bictegravir plus lenacapavir — is more effective than complex regimens are, according to results from a phase 2 study of people with HIV who are ...

Please provide your email address to receive an email when new articles are posted on . Overall, 94.2% of patients treated with ISL+LEN and 92.3% with B/F/TAF maintained viral suppression through week ...

Most transfeminine people support OTC access to PrEP for HIV prevention as means to eliminate burden and costs of clinical visits and laboratory testing.

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...

24.1% of HIV participants on ViiV Healthcare's therapy experienced regimen failure compared to 38.5% on standard care. Long-acting injectable HIV treatment showed superior efficacy in maintaining ...

A total of 300 successive cases of patients with HIV/AIDS with neurologic manifestations were studied. These patients were selected from internal medicine, neurology, and retroviral clinics/wards, ...

SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ("Ainos" or the "Company"), pioneer of low-dose oral interferon therapeutics, today announced significant ...